Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06084481 trial: what clinicians have said so far
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- NCT06084481 ↗
- Recruiting
- AbbVie
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06084481 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06084481 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X, typically up to 9 once built | |
| 1 post on Bluesky, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma; Platinum Resistant High Grade Epithelial Ovarian Cancer
- Interventions
- ABBV-400; Itraconazole (ITZ); Bevacizumab
- Arms
- Cohort 1: Hepatocellular Carcinoma (HCC) · Experimental
- Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC) · Experimental
- Cohort 3: Biliary Tract Cancers (BTC) · Experimental
- Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC) · Experimental
- Cohort 5: Triple Negative Breast Cancer (TNBC) · Experimental
- Cohort 6: Hormone Receptor+/HER2-breast Cancer (HR+/HER2-BC) · Experimental
- Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC) · Experimental
- Cohort 8: PROC/Primary Peritoneal/Fallopian Tube Cancer · Experimental
- Cohort 9: Drug-Drug Interaction · Experimental
- Cohort 10: PROC/Primary Peritoneal/Fallopian Tube Cancer · Experimental
- Enrollment
- 325 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Number of Participants with Adverse Events (AEs)
- Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate
- AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate
- Sponsor
- AbbVie
- Start
- Nov 9, 2023
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06084481 · updated Oct 14, 2026